Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers

References

• Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26(14):1816–10. doi:10.1177/1352458520970841.
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58. doi:10.1038/nri3871.
   PubMed Web of Science ®Google Scholar
• Bishop M, Rumrill PD, Bishop M, Rumrill PD. Multiple sclerosis: etiology, symptoms, incidence and prevalence, and implications for community living and employment. Work. 2015;52(4):725–34. doi:10.3233/wor-152200.
   PubMedGoogle Scholar
• Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9(3116). doi:10.3389/fimmu.2018.03116.
   Google Scholar
• Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16(Suppl 6):s53–59. doi:10.7861/clinmedicine.16-6-s53.
   PubMedGoogle Scholar
• Duffy SS, Keating BA, Moalem-Taylor G. Adoptive transfer of regulatory T cells as a promising immunotherapy for the treatment of multiple sclerosis. Front Neurosci. 2019;13(1107). doi:10.3389/fnins.2019.01107.
   PubMedGoogle Scholar
• Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545–55. doi:10.12998/wjcc.v3.i7.545.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20. doi:10.1056/NEJMoa1606468.
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (expand): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–73. doi:10.1016/s0140-6736(18)30475-6.
   PubMed Web of Science ®Google Scholar
• Baeten P, Van Zeebroeck L, Kleinewietfeld M, Hellings N, Broux B. Improving the efficacy of regulatory T cell therapy. Clin Rev Allergy Immunol. 2022;62:1–19. doi:10.1007/s12016-021-08866-1.
   PubMed Web of Science ®Google Scholar
• Chwojnicki K, Iwaszkiewicz-Grześ D, Jankowska A, Zieliński M, Łowiec P, Gliwiński M, Grzywińska M, Kowalczyk K, Konarzewska A, Glasner P, et al. Administration of CD4+CD25highCD127−FOXP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: a Phase 1 Study. BioDrugs. 2021;35(1):47–60. doi:10.1007/s40259-020-00462-7.
   PubMed Web of Science ®Google Scholar
• Dombrowski Y, O’Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, Fleville S, Eleftheriadis G, Zhao C, Naughton M, et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci. 2017;20(5):674–80. doi:10.1038/nn.4528.
   PubMed Web of Science ®Google Scholar
• McIntyre LL, Greilach SA, Othy S, Sears-Kraxberger I, Wi B, Ayala-Angulo J, Vu E, Pham Q, Silva J, Dang K, et al. Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant. Neurobiol Dis. 2020;140:104868. doi:10.1016/j.nbd.2020.104868.
   PubMed Web of Science ®Google Scholar
• Plaisted WC, Zavala A, Hingco E, Tran H, Coleman R, Lane TE, Loring JF, Walsh CM, Chen HCI. Remyelination is correlated with regulatory T cell induction following human embryoid body-derived neural precursor cell transplantation in a viral model of multiple sclerosis. PLoS One. 2016;11(6):e0157620. doi:10.1371/journal.pone.0157620.
   PubMed Web of Science ®Google Scholar
• Dittmer M, Young A, O’Hagan T, Eleftheriadis G, Bankhead P, Dombrowski Y, Medina RJ, Fitzgerald DC. Characterization of a murine mixed neuron-glia model and cellular responses to regulatory T cell-derived factors. Mol Brain. 2018;11(1):25. doi:10.1186/s13041-018-0367-6.
   PubMedGoogle Scholar
• Wang J, Xie L, Yang C, Ren C, Zhou K, Wang B, Zhang Z, Wang Y, Jin K, Yang GY. Activated regulatory T cell regulates neural stem cell proliferation in the subventricular zone of normal and ischemic mouse brain through interleukin 10. Front Cell Neurosci. 2015;9:361. doi:10.3389/fncel.2015.00361.
   PubMed Web of Science ®Google Scholar
• Ito M, Komai K, Mise-Omata S, Iizuka-Koga M, Noguchi Y, Kondo T, Sakai R, Matsuo K, Nakayama T, Yoshie O, et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature. 2019;2019565(7738):246–50. doi:10.1038/s41586-018-0824-5.
   Google Scholar
• Kipnis J, Avidan H, Caspi RR, Schwartz M. Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc Natl Acad Sci U S A. 2004;101(Suppl 2(Suppl 2)):14663–69. doi:10.1073/pnas.0404842101.
   PubMedGoogle Scholar
• Cramer SP, Simonsen H, Frederiksen JL, Rostrup E, Larsson HBW. Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by mri. NeuroImage. 2014;4:182–89. doi:10.1016/j.nicl.2013.12.001.
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the cns castle. Fluids Barriers CNS. 2011;8(1):4. doi:10.1186/2045-8118-8-4.
   PubMedGoogle Scholar
• Ortiz GG, Pacheco-Moisés FP, Macías-Islas M, Flores-Alvarado LJ, Mireles-Ramírez MA, González-Renovato ED, Hernández-Navarro VE, Sánchez-López AL, Alatorre-Jiménez MA. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014;45(8):687–97. doi:10.1016/j.arcmed.2014.11.013.
   PubMed Web of Science ®Google Scholar
• Burns J, Bartholomew B, Lobo S. Isolation of myelin basic protein-specific t cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann Neurol. 1999;45(1):33–39. doi:10.1002/1531-8249(199901)45:1<33:AID-ART7>3.0.CO;2-G.
   PubMed Web of Science ®Google Scholar
• Olsson T, Zhi WW, Höjeberg B, Kostulas V, Jiang YP, Anderson G, Ekre HP, Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest. 1990;86(3):981–85. doi:10.1172/jci114800.
   PubMed Web of Science ®Google Scholar
• Montes M, Zhang X, Berthelot L, Laplaud DA, Brouard S, Jin J, Rogan S, Armao D, Jewells V, Soulillou JP, et al. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin Immunol. 2009;130(2):133–44. doi:10.1016/j.clim.2008.08.030.
   PubMed Web of Science ®Google Scholar
• Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8(5):500–08. doi:10.1038/nm0502-500.
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172(1):146–55. doi:10.2353/ajpath.2008.070690.
   PubMed Web of Science ®Google Scholar
• Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A. Preferential recruitment of interferon-gamma-expressing Th17 cells in multiple sclerosis. Ann Neurol. 2009;66(3):390–402. doi:10.1002/ana.21748.
   PubMed Web of Science ®Google Scholar
• Edwards LJ, Robins RA, Constantinescu CS. Th17/Th1 phenotype in demyelinating disease. Cytokine. 2010;50(1):19–23. doi:10.1016/j.cyto.2009.12.003.
   PubMed Web of Science ®Google Scholar
• van Langelaar J, van der Vuurst de Vries RM, Janssen M, Wierenga-Wolf AF, Spilt IM, Siepman TA, Dankers W, Verjans G, de Vries HE, Lubberts E, et al. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain. 2018;141(5):1334–49. doi:10.1093/brain/awy069.
   PubMedGoogle Scholar
• Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857–63. doi:10.1038/ni.1767.
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10(8):864–71. doi:10.1038/ni.1770.
   PubMed Web of Science ®Google Scholar
• Perriard G, Mathias A, Enz L, Canales M, Schluep M, Gentner M, Schaeren-Wiemers N, Du Pasquier RA. Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. J Neuroinflammation. 2015;12(119). doi:10.1186/s12974-015-0335-3.
   PubMedGoogle Scholar
• Wing AC, Hygino J, Ferreira TB, Kasahara TM, Barros PO, Sacramento PM, Andrade RM, Camargo S, Rueda F, Alves-Leon SV, et al. Interleukin-17- and interleukin-22-secreting myelin-specific CD4 + T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients. Immunology. 2016;147(2):212–20. doi:10.1111/imm.12552.
   PubMed Web of Science ®Google Scholar
• Almolda B, Costa M, Montoya M, González B, Castellano B, Villoslada P. Increase in Th17 and T-reg lymphocytes and decrease of IL22 correlate with the recovery phase of acute EAE in rat. PLoS One. 2011;6(11):e27473. doi:10.1371/journal.pone.0027473.
   PubMed Web of Science ®Google Scholar
• Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173–75. doi:10.1038/nm1651.
   PubMed Web of Science ®Google Scholar
• Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015;5(9):e00362. doi:10.1002/brb3.362.
   PubMed Web of Science ®Google Scholar
• Hermans D, Houben E, Baeten P, Slaets H, Janssens K, Hoeks C, Hosseinkhani B, Duran G, Bormans S, Gowing E, et al. Oncostatin M triggers brain inflammation by compromising blood–brain barrier integrity. Acta Neuropathol. 2022;144(2):259–81. doi:10.1007/s00401-022-02445-0.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67(4):452–61. doi:10.1002/ana.21939.
   PubMed Web of Science ®Google Scholar
• Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A. Distinct effector cytokine profiles of memory and naive human b cell subsets and implication in multiple sclerosis. J Immunol. 2007;178(10):6092–99. doi:10.4049/jimmunol.178.10.6092.
   PubMed Web of Science ®Google Scholar
• Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, et al. Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis. Cell. 2018;175(1):85–100.e123. doi:10.1016/j.cell.2018.08.011.
   PubMed Web of Science ®Google Scholar
• Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA. B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021;17(7):399–414. doi:10.1038/s41582-021-00498-5.
   PubMed Web of Science ®Google Scholar
• Mancinelli CR, Rossi N, Capra R. Ocrelizumab for the treatment of multiple sclerosis: safety, efficacy, and pharmacology. Ther Clin Risk Manag. 2021;17:765–76. doi:10.2147/tcrm.S282390.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34. doi:10.1056/NEJMoa1601277.
   PubMed Web of Science ®Google Scholar
• Vogel DYS, Vereyken EJF, Glim JE, Heijnen PDAM, Moeton M, van der Valk P, Amor S, Teunissen CE, van Horssen J, Dijkstra CD. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013;10(1):809. doi:10.1186/1742-2094-10-35.
   Google Scholar
• Kouwenhoven M, Teleshova N, Ozenci V, Press R, Link H. Monocytes in multiple sclerosis: phenotype and cytokine profile. J Neuroimmunol. 2001;112(1–2):197–205. doi:10.1016/s0165-5728(00)00396-9.
   PubMed Web of Science ®Google Scholar
• Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci. 2011;14(9):1142–49. doi:10.1038/nn.2887.
   PubMed Web of Science ®Google Scholar
• Elieh-Ali-Komi D, Cao Y. Role of mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Rev Allergy Immunol. 2017;52(3):436–45. doi:10.1007/s12016-016-8595-y.
   PubMed Web of Science ®Google Scholar
• Janssens I, Cools N. Regulating the regulators: is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity? Cell Immunol. 2020;358:104236. doi:10.1016/j.cellimm.2020.10423610.1016/j.cellimm.2020.104236.
   PubMed Web of Science ®Google Scholar
• Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. Il-2 is essential for tgf-beta to convert naive CD4+CD25- cells to CD25+FOXP3+ regulatory T cells and for expansion of these cells. J Immunol. 2007;178(4):2018–27. doi:10.4049/jimmunol.178.4.2018.
   PubMed Web of Science ®Google Scholar
• Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 2005;105(3):1162–69. doi:10.1182/blood-2004-03-1211.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-Hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H. Pathogenic conversion of FOXP3+ T cells into th17 cells in autoimmune arthritis. Nat Med. 2014;20(1):62–68. doi:10.1038/nm.3432.
   PubMed Web of Science ®Google Scholar
• Bhaskaran N, Cohen S, Zhang Y, Weinberg A, Pandiyan P. Tlr-2 signaling promotes IL-17a production in CD4+CD25+FOXP3+ regulatory cells during oropharyngeal candidiasis. Pathogens. 2015;4(1):90–110. doi:10.3390/pathogens4010090.
   PubMedGoogle Scholar
• Mishra S, Srinivasan S, Ma C, Zhang N. CD8(+) regulatory T cell - a mystery to be revealed. Front Immunol. 2021;12(708874). doi:10.3389/fimmu.2021.708874.
   Google Scholar
• Hasan MM, Thompson-Snipes L, Klintmalm G, Demetris AJ, O’Leary J, Oh S, Joo H. CD24(hi)CD38(hi) and CD24(hi)CD27(+) human regulatory b cells display common and distinct functional characteristics. J Immunol. 2019;203(8):2110–20. doi:10.4049/jimmunol.1900488.
   PubMed Web of Science ®Google Scholar
• Seitz C, Joly A-L, Fang F, Frith K, Gray P, Andersson J. The FOXP3 full-length isoform controls the lineage-stability of CD4+FOXP3+ regulatory T cells. Clinical Immunology. 2022;237(108957). doi:10.1016/j.clim.2022.108957.
   PubMedGoogle Scholar
• Sambucci M, Gargano F, De Rosa V, De Bardi M, Picozza M, Placido R, Ruggieri S, Capone A, Gasperini C, Matarese G, et al. FOXP3 isoforms and pd-1 expression by T regulatory cells in multiple sclerosis. Sci Rep. 2018;8(1):3674. doi:10.1038/s41598-018-21861-5.
   PubMedGoogle Scholar
• De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C, Romano A, De Simone S, Procaccini C, La Rocca C, et al. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. 2015;16(11):1174–84. doi:10.1038/ni.3269.
   PubMed Web of Science ®Google Scholar
• Du J, Wang Q, Yang S, Chen S, Fu Y, Spath S, Domeier P, Hagin D, Anover-Sombke S, Haouili M, et al. FOXP3 exon 2 controls T reg stability and autoimmunity. Sci Immunol. 2022;7(72):eabo5407. doi:10.1126/sciimmunol.abo5407.
   PubMed Web of Science ®Google Scholar
• Li YF, Zhang SX, Ma XW, Xue YL, Gao C, Li XY, Xu AD. The proportion of peripheral regulatory T cells in patients with multiple sclerosis: a meta-analysis. Mult Scler Relat Disord. 2019;28:75–80. doi:10.1016/j.msard.2018.12.019.
   PubMed Web of Science ®Google Scholar
• Kouchaki E, Salehi M, Reza Sharif M, Nikoueinejad H, Akbari H. Numerical status of CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) regulatory T cells in multiple sclerosis. Iran J Basic Med Sci. 2014;17(4):250–55. doi:10.22038/ijbms.2014.2582.
   PubMed Web of Science ®Google Scholar
• Venken K, Hellings N, Thewissen M, Somers V, Hensen K, Rummens JL, Medaer R, Hupperts R, Stinissen P. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology. 2008;123(1):79–89. doi:10.1111/j.1365-2567.2007.02690.x.
   PubMed Web of Science ®Google Scholar
• Fritzsching B, Haas J, König F, Kunz P, Fritzsching E, Pöschl J, Krammer PH, Brück W, Suri-Payer E, Wildemann B, et al. Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PLoS One. 2011;6(3):e17988. doi:10.1371/journal.pone.0017988.
   PubMed Web of Science ®Google Scholar
• Feger U, Luther C, Poeschel S, Melms A, Tolosa E, Wiendl H. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol. 2007;147(3):412–18. doi:10.1111/j.1365-2249.2006.03271.x.
   PubMed Web of Science ®Google Scholar
• Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation. 2017;14(1):117. doi:10.1186/s12974-017-0892-8.
   PubMed Web of Science ®Google Scholar
• Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199(7):971–79. doi:10.1084/jem.20031579.
   PubMed Web of Science ®Google Scholar
• Haas J, Hug A, Viehöver A, Fritzsching B, Falk CS, Filser A, Vetter T, Milkova L, Korporal M, Fritz B, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol. 2005;35(11):3343–52. doi:10.1002/eji.200526065.
   PubMed Web of Science ®Google Scholar
• Kumar M, Putzki N, Limmroth V, Remus R, Lindemann M, Knop D, Mueller N, Hardt C, Kreuzfelder E, Grosse-Wilde H. CD4+CD25+FOXP3+ t lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol. 2006;180(1–2):178–84. doi:10.1016/j.jneuroim.2006.08.003.
   PubMed Web of Science ®Google Scholar
• Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol. 2008;28(6):697–706. doi:10.1007/s10875-008-9236-x.
   PubMed Web of Science ®Google Scholar
• Okada Y, Ochi H, Fujii C, Hashi Y, Hamatani M, Ashida S, Kawamura K, Kusaka H, Matsumoto S, Nakagawa M, et al. Signaling via toll-like receptor 4 and CD40 in b cells plays a regulatory role in the pathogenesis of multiple sclerosis through interleukin-10 production. J Autoimmun. 2018;88:103–13. doi:10.1016/j.jaut.2017.10.011.
   PubMed Web of Science ®Google Scholar
• Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Cohen Tervaert JW, Hupperts R, Damoiseaux J. Reduction in IL-10 producing b cells (breg) in multiple sclerosis is accompanied by a reduced naïve/memory breg ratio during a relapse but not in remission. J Neuroimmunol. 2011;239(1–2):80–86. doi:10.1016/j.jneuroim.2011.08.019.
   PubMed Web of Science ®Google Scholar
• Cencioni MT, Ali R, Nicholas R, Muraro PA. Defective cd19+cd24(hi)cd38(hi) transitional b-cell function in patients with relapsing-remitting MS. Mult Scler. 2021;27(8):1187–97. doi:10.1177/1352458520951536.
   PubMed Web of Science ®Google Scholar
• Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity. 2013;39(5):949–62. doi:10.1016/j.immuni.2013.10.016.
   PubMed Web of Science ®Google Scholar
• Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, FOXP3+ regulatory T cells in human autoimmune disease. Nat Med. 2011;17(6):673–75. doi:10.1038/nm.2389.
   PubMed Web of Science ®Google Scholar
• Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Bäckström BT, Sobel RA, Wucherpfennig KW, Strom TB, et al. Myelin-specific regulatory T cells accumulate in the cns but fail to control autoimmune inflammation. Nat Med. 2007;13(4):423–31. doi:10.1038/nm1564.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol. 2005;175(5):3025–32. doi:10.4049/jimmunol.175.5.3025.
   PubMed Web of Science ®Google Scholar
• Ronin E, Pouchy C, Khosravi M, Hilaire M, Grégoire S, Casrouge A, Kassem S, Sleurs D, Martin GH, Chanson N, et al. Tissue-restricted control of established central nervous system autoimmunity by tnf receptor 2–expressing Treg cells. Proc Natl Acad Sci. 2021;118(13):e2014043118. doi:10.1073/pnas.2014043118.
   PubMed Web of Science ®Google Scholar
• Kurschus FC. T cell mediated pathogenesis in EAE: molecular mechanisms. Biomed J. 2015;38(3):183–93. doi:10.4103/2319-4170.155590.
   PubMed Web of Science ®Google Scholar
• Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol. 2004;25(3):132–37. doi:10.1016/j.it.2004.01.007.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat Neurosci. 2012;15(8):1074–77. doi:10.1038/nn.3168.
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bradl M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 2017;133(2):223–44. doi:10.1007/s00401-016-1631-4.
   PubMed Web of Science ®Google Scholar
• Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, McQuaid S. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol. 2010;229(1–2):180–91. doi:10.1016/j.jneuroim.2010.08.011.
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (ms). Br J Pharmacol. 2011;164(4):1079–106. doi:10.1111/j.1476-5381.2011.01302.x.
   PubMed Web of Science ®Google Scholar
• Jin S, Sonobe Y, Kawanokuchi J, Horiuchi H, Cheng Y, Wang Y, Mizuno T, Takeuchi H, Suzumura A. Interleukin-34 restores blood-brain barrier integrity by upregulating tight junction proteins in endothelial cells. PLoS One. 2014;9(12):e115981. doi:10.1371/journal.pone.0115981.
   PubMed Web of Science ®Google Scholar
• Lopes Pinheiro MA, Kooij G, Mizee MR, Kamermans A, Enzmann G, Lyck R, Schwaninger M, Engelhardt B, de Vries HE. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim Biophys Acta. 2016;1862(3):461–71. doi:10.1016/j.bbadis.2015.10.018.
   PubMed Web of Science ®Google Scholar
• Broux B, Gowing E, Prat A. Glial regulation of the blood-brain barrier in health and disease. Semin Immunopathol. 2015;37(6):577–90. doi:10.1007/s00281-015-0516-2.
   PubMed Web of Science ®Google Scholar
• Doerck S, Göbel K, Weise G, Schneider-Hohendorf T, Reinhardt M, Hauff P, Schwab N, Linker R, Mäurer M, Meuth SG, et al. Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. PLoS One. 2010;5(11):e15478. doi:10.1371/journal.pone.0015478.
   PubMed Web of Science ®Google Scholar
• Steiner O, Coisne C, Cecchelli R, Boscacci R, Deutsch U, Engelhardt B, Lyck R. Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-resistant T cell arrest, polarization, and directed crawling on blood-brain barrier endothelium. J Immunol. 2010;185(8):4846–55. doi:10.4049/jimmunol.0903732.
   PubMed Web of Science ®Google Scholar
• Abadier M, Haghayegh Jahromi N, Cardoso Alves L, Boscacci R, Vestweber D, Barnum S, Deutsch U, Engelhardt B, Lyck R. Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood-brain barrier. Eur J Immunol. 2015;45(4):1043–58. doi:10.1002/eji.201445125.
   PubMed Web of Science ®Google Scholar
• Losy J. Is MS an inflammatory or primary degenerative disease? J Neural Transm (Vienna). 2013;120(10):1459–62. doi:10.1007/s00702-013-1079-9.
   PubMed Web of Science ®Google Scholar
• Blecharz KG, Haghikia A, Stasiolek M, Kruse N, Drenckhahn D, Gold R, Roewer N, Chan A, Förster CY. Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cend incubated with sera from patients with multiple sclerosis. Mult Scler. 2010;16(3):293–302. doi:10.1177/1352458509358189.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Heales SJ, Land JM, Thompson EJ. The potential role of nitric oxide in multiple sclerosis. Mult Scler. 1998;4(3):212–16. doi:10.1177/135245859800400323.
   PubMed Web of Science ®Google Scholar
• Ortiz GG, Macías-Islas MÁ, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers. 2009;26(1):35–39. doi:10.3233/DMA-2009-0602.
   PubMed Web of Science ®Google Scholar
• Nishihara H, Perriot S, Gastfriend BD, Steinfort M, Cibien C, Soldati S, Matsuo K, Guimbal S, Mathias A, Palecek SP, et al. Intrinsic blood–brain barrier dysfunction contributes to multiple sclerosis pathogenesis. Brain. 2022. doi:10.1093/brain/awac019.
   PubMed Web of Science ®Google Scholar
• Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162:5317–26.
   PubMed Web of Science ®Google Scholar
• Fisson S, Darrasse-Jèze G, Litvinova E, Septier F, Klatzmann D, Liblau R, Salomon BL. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med. 2003;198(5):737–46. doi:10.1084/jem.20030686.
   PubMed Web of Science ®Google Scholar
• Schneider-Hohendorf T, Stenner M-P, Weidenfeller C, Zozulya AL, Simon OJ, Schwab N, Wiendl H. Regulatory t cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. Eur J Immunol. 2010;40(12):3581–90. doi:10.1002/eji.201040558.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang SG, Kim CH. FOXP3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues. J Immunol. 2007;178(1):301–11. doi:10.4049/jimmunol.178.1.301.
   PubMed Web of Science ®Google Scholar
• Gültner S, Kuhlmann T, Hesse A, Weber JP, Riemer C, Baier M, Hutloff A. Reduced Treg frequency in LFA-1-deficient mice allows enhanced T effector differentiation and pathology in EAE. Eur J Immunol. 2010;40(12):3403–12. doi:10.1002/eji.201040576.
   PubMed Web of Science ®Google Scholar
• Welsh CT, Rose JW, Hill KE, Townsend JJ. Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 alpha. J Neuroimmunol. 1993;43(1–2):161–67. doi:10.1016/0165-5728(93)90087-f.
   PubMed Web of Science ®Google Scholar
• Glatigny S, Duhen R, Arbelaez C, Kumari S, Bettelli E. Integrin alpha l controls the homing of regulatory T cells during cns autoimmunity in the absence of integrin alpha 4. Sci Rep. 2015;5:7834. doi:10.1038/srep07834.
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, Rudensky AY. CD4+ regulatory T cells control Th17 responses in a stat3-dependent manner. Science. 2009;326(5955):986–91. doi:10.1126/science.1172702.
   PubMed Web of Science ®Google Scholar
• Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10(6):595–602. doi:10.1038/ni.1731.
   PubMed Web of Science ®Google Scholar
• Müller M, Carter SL, Hofer MJ, Manders P, Getts DR, Getts MT, Dreykluft A, Lu B, Gerard C, King NJ, et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol. 2007;179(5):2774–86. doi:10.4049/jimmunol.179.5.2774.
   PubMed Web of Science ®Google Scholar
• Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, Walker LS, Adams DH. Epithelial inflammation is associated with ccl28 production and the recruitment of regulatory T cells expressing ccr10. J Immunol. 2006;177(1):593–603. doi:10.4049/jimmunol.177.1.593.
   PubMed Web of Science ®Google Scholar
• Debes GF, Dahl ME, Mahiny AJ, Bonhagen K, Campbell DJ, Siegmund K, Erb KJ, Lewis DB, Kamradt T, Hamann A. Chemotactic responses of IL-4-, IL-10-, and IFN-γ-producing CD4+ T cells depend on tissue origin and microbial stimulus. J Immunol. 2006;176(1):557–66. doi:10.4049/jimmunol.176.1.557.
   PubMed Web of Science ®Google Scholar
• Sørensen TL, Trebst C, Kivisäkk P, Klaege KL, Majmudar A, Ravid R, Lassmann H, Olsen DB, Strieter RM, Ransohoff RM, et al. Multiple sclerosis: a study of cxcl10 and cxcr3 co-localization in the inflamed central nervous system. J Neuroimmunol. 2002;127(1–2):59–68. doi:10.1016/s0165-5728(02)00097-8.
   PubMed Web of Science ®Google Scholar
• Balashov KE, Rottman JB, Weiner HL, Hancock WW. Ccr5(+) and cxcr3(+) T cells are increased in multiple sclerosis and their ligands mip-1alpha and ip-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A. 1999;96(12):6873–78. doi:10.1073/pnas.96.12.6873.
   PubMed Web of Science ®Google Scholar
• Kivisäkk P, Trebst C, Liu Z, Tucky BH, Sørensen TL, Rudick RA, Mack M, Ransohoff RM. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of cns inflammation: implications for cns trafficking. Clin Exp Immunol. 2002;129(3):510–18. doi:10.1046/j.1365-2249.2002.01947.x.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, Martin-Orozco N, Kang HS, Ma L, Panopoulos AD, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol. 2008;181(12):8391–401. doi:10.4049/jimmunol.181.12.8391.
   PubMed Web of Science ®Google Scholar
• Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rötzschke O, Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset. Blood. 2005;105(7):2877–86. doi:10.1182/blood-2004-07-2505.
   PubMed Web of Science ®Google Scholar
• Villares R, Cadenas V, Lozano M, Almonacid L, Zaballos A, Martínez AC, Varona R. CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues. Eur J Immunol. 2009;39(6):1671–81. doi:10.1002/eji.200839123.
   PubMed Web of Science ®Google Scholar
• Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D’Ambrosio D. Unique chemotactic response profile and specific expression of chemokine receptors ccr4 and ccr8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001;194(6):847–53. doi:10.1084/jem.194.6.847.
   PubMed Web of Science ®Google Scholar
• Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, Lira SA, Karin N. Ccr8(+)FOXP3(+) t(reg) cells as master drivers of immune regulation. Proc Natl Acad Sci U S A. 2017;114(23):6086–91. doi:10.1073/pnas.1621280114.
   PubMed Web of Science ®Google Scholar
• Coghill JM, Fowler KA, West ML, Fulton LM, van Deventer H, McKinnon KP, Vincent BG, Lin K, Panoskaltsis-Mortari A, Cook DN, et al. Cc chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. Blood. 2013;122(5):825–36. doi:10.1182/blood-2012-06-435735.
   PubMed Web of Science ®Google Scholar
• Jatczak-Pawlik I, Wolinski P, Książek-Winiarek D, Pietruczuk M, Glabinski A. CCR6 blockade on regulatory T cells ameliorates experimental model of multiple sclerosis. Cent Eur J Immunol. 2020;45(3):256–66. doi:10.5114/ceji.2020.101241.
   PubMed Web of Science ®Google Scholar
• Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rötzschke O, Falk K. CD49d provides access to “untouched” human FOXP3+ Treg free of contaminating effector cells. Blood. 2009;113(4):827–36. doi:10.1182/blood-2008-04-150524.
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356(6364):63–66. doi:10.1038/356063a0.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. doi:10.1056/NEJMoa044397.
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23. doi:10.1056/NEJMoa020696.
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and mri effects. Neurology. 2004;62(11):2038–43. doi:10.1212/01.wnl.0000128136.79044.d6.
   PubMed Web of Science ®Google Scholar
• Tischner D, Weishaupt A, van den Brandt J, Müller N, Beyersdorf N, Ip CW, Toyka KV, Hünig T, Gold R, Kerkau T, et al. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain. 2006;129(Pt 10):2635–47. doi:10.1093/brain/awl213.
   PubMedGoogle Scholar
• Hong GU, Kim NG, Jeoung D, Ro JY. Anti-CD40 Ab-or 8-oxo-dG-enhanced Treg cells reduce development of experimental autoimmune encephalomyelitis via down-regulating migration and activation of mast cells. J Neuroimmunol. 2013;260(1–2):60–73. doi:10.1016/j.jneuroim.2013.04.002.
   PubMed Web of Science ®Google Scholar
• Koutrolos M, Berer K, Kawakami N, Wekerle H, Krishnamoorthy G. Treg cells mediate recovery from EAE by controlling effector T cell proliferation and motility in the cns. Acta Neuropathol Commun. 2014;2(163). doi:10.1186/s40478-014-0163-1.
   PubMedGoogle Scholar
• Othy S, Jairaman A, Dynes JL, Dong TX, Tune C, Yeromin AV, Zavala A, Akunwafo C, Chen F, Parker I, et al. Regulatory T cells suppress Th17 cell Ca 2+ signaling in the spinal cord during murine autoimmune neuroinflammation. Proc Natl Acad Sci U S A. 2020;117(33):20088–99. doi:10.1073/pnas.2006895117.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, et al. Umbilical cord blood–derived T regulatory cells to prevent gvhd: kinetics, toxicity profile, and clinical effect. Blood. 2016;127(8):1044–51. doi:10.1182/blood-2015-06-653667.
   PubMed Web of Science ®Google Scholar
• Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− T regulatory cells. Clinical Immunology. 2009;133(1):22–26. doi:10.1016/j.clim.2009.06.001.
   PubMed Web of Science ®Google Scholar
• Theil A, Tuve S, Oelschlägel U, Maiwald A, Döhler D, Oßmann D, Zenkel A, Wilhelm C, Middeke JM, Shayegi N, et al. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy. 2015;17(4):473–86. doi:10.1016/j.jcyt.2014.11.005.
   PubMed Web of Science ®Google Scholar
• Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E, et al. Hla-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124(4):638–44. doi:10.1182/blood-2014-03-564401.
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory crohn’s disease. Gastroenterology. 2012;143(5):1207–17.e1202. doi:10.1053/j.gastro.2012.07.116.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315):315ra189. doi:10.1126/scitranslmed.aad4134.
   PubMed Web of Science ®Google Scholar
• Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight. 2021;6(18). doi:10.1172/jci.insight.147474
   Web of Science ®Google Scholar
• Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, Cudkowicz ME, Appel SH. Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e465. doi:10.1212/nxi.0000000000000465.
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Kim BS, Mooney K, Karaba AH, D’Alessio FR. Regulatory T cells for treating patients with covid-19 and acute respiratory distress syndrome: two case reports. Ann Intern Med. 2020;173(10):852–53. doi:10.7326/l20-0681.
   PubMed Web of Science ®Google Scholar
• Lassiter G, Melancon C, Rooney T, Murat AM, Kaye JS, Kaye AM, Kaye RJ, Cornett EM, Kaye AD, Shah RJ, et al. Ozanimod to treat relapsing forms of multiple sclerosis: a comprehensive review of disease, drug efficacy and side effects. Neurol Int. 2020;12(3):89–108. doi:10.3390/neurolint12030016.
   PubMed Web of Science ®Google Scholar
• De Paula Pohl A, Schmidt A, Zhang AH, Maldonado T, Königs C, Scott DW. Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression. Cell Immunol. 2020;358:104222. doi:10.1016/j.cellimm.2020.104222.
   PubMed Web of Science ®Google Scholar
• Gijbels K, Brocke S, Abrams JS, Steinman L. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol Med. 1995;1(7):795–805. doi:10.1007/BF03401894.
   PubMed Web of Science ®Google Scholar
• Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hünig T, Kerkau T, Gold R. Selective targeting of regulatory T cells with cd28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med. 2005;202(3):445–55. doi:10.1084/jem.20051060.
   PubMed Web of Science ®Google Scholar
• Baeten P, Hellings N, Broux B. In vitro tailoring of regulatory T cells prior to cell therapy. Trends Mol Med. 2020;26(11):1059–60. doi:10.1016/j.molmed.2020.08.008.
   PubMed Web of Science ®Google Scholar